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ABSTRACT
Human neutrophil elastase (HNE) is an important target for the development of novel and selective inhibi-
tors to treat inflammatory diseases, especially pulmonary pathologies. Here, we report the synthesis, struc-
ture–activity relationship analysis, and biological evaluation of a new series of HNE inhibitors with an
isoxazol-5(2H)-one scaffold. The most potent compound (2o) had a good balance between HNE inhibitory
activity (IC50 value ¼20nM) and chemical stability in aqueous buffer (t1/2¼8.9 h). Analysis of reaction kinet-
ics revealed that the most potent isoxazolone derivatives were reversible competitive inhibitors of HNE.
Furthermore, since compounds 2o and 2s contain two carbonyl groups (2-N-CO and 5-CO) as possible
points of attack for Ser195, the amino acid of the active site responsible for the nucleophilic attack, dock-
ing studies allowed us to clarify the different roles played by these groups.
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New potent HNE inhibitors
IC50 = 20-96 nM
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Introduction
Human neutrophil elastase (HNE) is a member of the chymotrypsin
superfamily of serine proteases and is primarily expressed in neu-
trophil azurophilic granules1,2. It is one of the few proteases able
to degrade the matrix protein elastin, but can also degrade a var-
iety of extracellular other matrix proteins, such as fibronectin, col-
lagen, proteoglycans, and laminin3. Moreover, HNE plays a pivotal
role both in intracellular and extracellular innate immune
responses against bacteria4. HNE performs its proteolytic action on
the membranes of Gram-negative bacteria engulfed in neutrophil
phagolysosomes5 and in association with special structures called
“neutrophil extracellular traps” (NETs) that are extruded into the
extracellular space6. High molecular weight serine protease inhibi-
tors called SERPINs (e.g. alpha-1 antitrypsin (AAT), elafin, and
secretory leucocyte protease inhibitor) strictly regulate HNE activity
to prevent uncontrolled proteolysis, and alteration of the protea-
se–antiprotease balance7,8 plays an important role in some inflam-
matory diseases, mainly those involving the respiratory system. For
example, chronic obstructive pulmonary disease (COPD)9 is charac-
terised by an impaired protease–antiprotease balance. Likewise,
cystic fibrosis (CF)10, bronchiectasis (BE), pulmonary arterial hyper-
tension (PAH), acute lung injury (ALI), and adult respiratory distress
syndrome (ARDS)11,12 involve imbalances in protease–antiprotease
activities. HNE has also recently been implicated in the progression
of various types of cancer and other important neutrophil-driven
inflammatory diseases, such as rheumatoid arthritis and inflamma-
tory bowel disease13.
In the last three decades, research on the development of
innovative elastase inhibitors has resulted in the synthesis of a
number of new compounds, including peptide and non-peptide
derivatives14,15. Currently, Sivelestat (ElaspolVR 100) is the only
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non-peptide drug available for the treatment of ALI/ARDS16,
although it is only marketed in Japan and Korea. Sivelestat has
been also used in paediatric heart surgery with cardiopulmonary
bypass (CPB), where it attenuated the perioperative inflammatory
response due to release of neutrophil proteolytic enzymes such as
elastase17. Additionally, two potent and orally active candidates,
AZD9668 (Alvelestat, Astra Zeneca, Cambridge, UK)18,19 and BAY
85-8501 (Bayer HealthCare, Leverkusen, Germany)20, are in clinical
trials (Phase II) for patients with BE, CF, COPD, and pulmonary dis-
ease (Figure 1).
Our interest in the design and synthesis of new non-peptide
HNE inhibitors resulted from the discovery of a potent class of
HNE inhibitors with a N-benzoylindazole scaffold21,22. These com-
pounds had IC50 values in the low nanomolar range. Studies on
their mechanism of action demonstrated that these compounds
were competitive and pseudo-irreversible HNE inhibitors with
greater selectivity for HNE versus other serine proteases and had
appreciable chemical stability in aqueous buffer. Further work led
to additional interesting HNE inhibitors with cinnoline23 and
indole24 scaffolds.
In the present study, we report a novel class of HNE inhibitors
with an isoxazol-5(2H)-one core. We designed and synthesised
small and flexible molecules bearing alkyl groups at positions 3
and 4 or 4-unsubstituted derivatives, also introducing those sub-
stituents identified in our previous compound series21–23 to be
fundamental for HNE inhibitory activity.
Materials and methods
All melting points were determined on a B€uchi apparatus (New
Castle, DE) and are uncorrected. Extracts were dried over Na2SO4,
and the solvents were removed under reduced pressure. Merck F-
254 commercial plates (Merck, Durham, NC) were used for analyt-
ical TLC to follow the course of the reactions. Silica gel 60 (Merck
70–230 mesh, Merck, Durham, NC) was used for column chroma-
tography. 1H NMR, 13C NMR, HSQC, and HMBC spectra were
recorded on an Avance 400 instrument (Bruker Biospin Version
002 with SGU, Bruker Inc., Billerica, MA). Chemical shifts (d) are
reported in ppm to the nearest 0.01 ppm using the solvent as an
internal standard. Coupling constants (J values) are presented in
Hz as calculated using TopSpin 1.3 software (Nicolet Instrument
Corp., Madison, WI) and are rounded to the nearest 0.1 vHz. Mass
spectra (m/z) were recorded on an ESI-TOF mass spectrometer
(Brucker Micro TOF, Bruker Inc., Billerica, MA), and reported mass
values are within the error limits of ±5 ppm mass units.
Microanalyses indicated by the symbols of the elements or func-
tions were performed with a Perkin–Elmer 260 elemental analyser
(PerkinElmer, Inc., Waltham, MA) for C, H, and N, and the results
were within ±0.4% of the theoretical values, unless otherwise
stated. Reagents and starting material were commercially available.
The purity of all tested compounds is >95%. The crystal structure
of compound 2j was solved by single-crystal X-ray diffraction.
Chemistry. General procedure for synthesis of compounds (2a–s).
To a suspension of the appropriate substrates 1a–f25–29
(0.86mmol) in 10ml of anhydrous THF, 1.72mmol of sodium
hydride and 1.03mmol of the appropriate acyl/aroyl chloride were
added. The mixture was stirred at room temperature overnight.
The solvent was concentrated in vacuo to obtain the final com-
pounds 2a–s, which were purified by column chromatography
using cyclohexane/ethyl acetate (2:1 for 2a,i,s; 3:1 for
2e,g,h,j,k,p,q; 4:1 for 2c,l,m; and 5:1 for 2d,r] or toluene/ethyl acet-
ate 9.5:0.5 (2b,f,n,o) as eluents.
2-(Cyclopropanecarbonyl)-3,4-dimethylisoxazol-5(2H)-one (2a).
Yield¼ 32%; oil. 1H NMR (CDCl3-d1) d 1.02–1.07 (m, 2H, CH2
cC3H5), 1.12–1.17 (m, 2H, CH2 cC3H5), 1.82 (s, 3H, CH3), 2.34–2.40
(m, 1H, CH cC3H5), 2.49 (s, 3H, CH3). 13C NMR (CDCl3-d1) d 6.26
(CH3), 10.44 (CH2), 12.50 (CH), 13.77 (CH3), 102.41 (C), 153.33 (C),
167.77 (C), 168.74 (C). ESI-MS calcd. for C9H11NO3, 181.19; found:
m/z 182.08 [MþH]þ. Anal. C9H11NO3 (C, H, N).
3,4-Dimethyl-2-(3-methylbenzoyl)isoxazol-5(2H)-one (2b).
Yield¼ 30%; oil. 1H NMR (CDCl3-d1) d 1.75 (s, 3H, CH3), 2.05 (s, 3H,
CH3), 2.41 (s, 3H, CH3-Ph), 7.35 (t, 1H, Ar, J¼ 8.0 Hz), 7.44 (d, 1H, Ar,
J¼ 7.6 Hz), 7.80–7.85 (m, 2H, Ar). 13C NMR (CDCl3-d1) d 10.99
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Figure 1. HNE inhibitors.
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(CH3), 20.12 (CH3), 21.23 (CH3), 29.70 (C), 127.38 (CH), 128.65 (CH),
130.68 (CH), 135.28 (CH), 134.10 (C), 138.70 (C), 143.10 (C), 157.61
(C), 169.57 (C). ESI-MS calcd. for C13H13NO3, 231.25; found: m/z
232.09 [MþH]þ. Anal. C13H13NO3 (C, H, N).
2-(Cyclopropanecarbonyl)-4-ethyl-3-methylisoxazol-5(2H)-one (2c).
Yield¼ 26%; oil. 1H NMR (CDCl3-d1) d 0.98–1.05 (m, 2H,
CH2 cC3H5), 1.10 (t, 3H, CH2CH3, J¼ 7.6 Hz), 1.13–1.18 (m, 2H, CH2
cC3H5), 2.26 (q, 2H, CH2CH3, J¼ 7.6 Hz), 2.34–2.40 (m, 1H, CH
cC3H5), 2.50 (s, 3H, CH3). 13C NMR (CDCl3-d1) d 10.96 (CH2), 13.09
(CH3), 13.58 (CH3), 14.06 (CH), 15.53 (CH2), 108.58 (C), 153.56 (C),
167.87 (C), 169.34 (C). ESI-MS calcd. for C10H13NO3, 195.22; found:
m/z 196.09 [MþH]þ. Anal. C10H13NO3 (C, H, N).
4-Ethyl-3-methyl-2-(3-methylbenzoyl)isoxazol-5(2H)-one (2d).
Yield¼ 34%; oil. 1H NMR (CDCl3-d1) d 1.13 (t, 3H, CH2CH3,
J¼ 7.6 Hz), 2.31 (q, 2H, CH2CH3, J¼ 7.6 Hz), 2.39 (s, 3H, CH3), 2.61
(s, 3H, CH3-Ph), 7.30–7.37 (m, 2H, Ar), 7.61–7.66 (m, 2H, Ar).
13C
NMR (CDCl3-d1) d 12.99 (CH3), 13.90 (CH2), 15.13 (CH3), 21.34 (CH3),
109.02 (C), 126.61 (CH), 127.70 (CH), 129.75 (CH), 131.41 (C), 133.78
(CH), 138.18 (C), 154.31 (C), 163.72 (C), 167.41 (C). ESI-MS calcd. for
C14H15NO3, 245.27; found: m/z 246.11 [MþH]þ. Anal. C14H15NO3
(C, H, N).
2-(Cyclopropanecarbonyl)-3-ethyl-4-methylisoxazol-5(2H)-one (2e).
Yield¼ 54%; oil. 1H NMR (CDCl3-d1) d 0.97–1.05 (m, 2H, CH2
cC3H5), 1.13–1.18 (m, 2H, CH2 cC3H5), 1.20 (t, 3H, CH2CH3,
J¼ 7.2 Hz), 1.82 (s, 3H, CH3), 2.34–2.40 (m, 1H, CH cC3H5), 2.90 (q,
2H, CH2CH3, J¼ 7.2 Hz). 13C NMR (CDCl3-d1) d 6.03 (CH), 10.37
(CH2), 12.06 (CH3), 12.66 (CH3), 20.74 (CH2), 102.22 (C), 158.53 (C),
167.89 (C), 168.23 (C). ESI-MS calcd. for C10H13NO3, 195.22; found:
m/z 196.09 [MþH]þ. Anal. C10H13NO3 (C, H, N).
3-Ethyl-4-methyl-2-(3-methylbenzoyl)isoxazol-5(2H)-one (2f).
Yield¼ 10%; oil. 1H NMR (CDCl3-d1) d 1.30 (t, 3H, CH2CH3,
J¼ 7.6 Hz), 1.85 (s, 3H, CH3), 2.44 (s, 3H, CH3-Ph), 2.64 (q, 2H,
CH2CH3, J¼ 7.6 Hz), 7.41 (t, 1H, Ar, J¼ 7.6 Hz), 7.49 (d, 1H, Ar,
J¼ 7.6 Hz), 7.96 (d, 2H, Ar, J¼ 7.6 Hz). 13C NMR (CDCl3-d1) d 5.92
(CH3), 11.36 (CH3), 19.55 (CH2), 21.41 (CH3), 97.56 (C), 127.03 (C),
127.96 (CH), 128.76 (CH), 131.21 (CH), 135.47 (CH), 138.45 (C),
161.76 (C), 161.96 (C), 167.00 (C). ESI-MS calcd. for C14H15NO3,
245.27; found: m/z 246.11 [MþH]þ. Anal. C14H15NO3 (C, H, N).
Ethyl 2-(cyclopropanecarbonyl)-4-methyl-5-oxo-2,5-dihydroisoxa-
zole-3-carboxylate (2g). Yield¼ 38%; oil. 1H NMR (CDCl3-d1) d
1.11–1.16 (m, 2H, CH2 cC3H5), 1.17–1.23 (m, 2H, CH2 cC3H5), 1.35 (t,
3H, CH2CH3, J¼ 7.2 Hz), 1.95 (s, 3H, CH3), 2.25–2.31 (m, 1H, CH
cC3H5), 4.41 (q, 2H, CH2CH3, J¼ 7.2 Hz). 13C NMR (CDCl3-d1) d 6.89
(CH), 10.91 (CH2), 12.40 (CH3), 13.88 (CH3), 63.22 (CH2), 107.85 (C),
145.28 (C), 158.92 (C), 167.45 (C), 168.67 (C). ESI-MS calcd. for
C11H13NO5, 239.22; found: m/z 240.08 [MþH]þ. Anal. C11H13NO5
(C, H, N).
Ethyl 4-methyl-2-(3-methylbenzoyl)-5-oxo-2,5-dihydroisoxazole-3-
carboxylate (2h). Yield¼ 21%; oil. 1H NMR (CDCl3-d1) d 1.42 (t, 3H,
CH2CH3, J¼ 7.2 Hz), 2.08 (s, 3H, CH3), 2.44 (s, 3H, CH3-Ph), 4.45 (q,
2H, CH2CH3, J¼ 7.2 Hz), 7.42 (t, 1H, Ar, J¼ 7.6 Hz), 7.51 (d, 1H, Ar,
J¼ 7.6 Hz), 7.97 (d, 2H, Ar, J¼ 7.6 Hz). 13C NMR (CDCl3-d1) d 6.68
(CH3), 14.16 (CH3), 21.26 (CH3), 62.03 (CH2), 101.14 (C), 126.42 (C),
128.07 (CH), 128.90 (CH), 131.34 (CH), 135.89 (CH), 138.81 (C),
156.61 (C), 160.17 (C), 161.66 (C), 163.86 (C). ESI-MS calcd. for
C15H15NO5, 289.28; found: m/z 290.10 [MþH]þ. Anal. C15H15NO5
(C, H, N).
2-(Cyclopropanecarbonyl)-3-ethylisoxazol-5(2H)-one (2i).
Yield¼ 47%; mp ¼92–95 C (EtOH). 1H NMR (CDCl3-d1) d 1.05–1.10
(m, 2H, CH2 cC3H5), 1.14–1.19 (m, 2H, CH2 cC3H5), 1.25 (t, 3H,
CH2CH3, J¼ 7.4 Hz), 2.36–2.42 (m, 1H, CH cC3H5), 2.95 (q, 2H,
CH2CH3, J¼ 7.4 Hz), 5.32 (s, 1H, CH). 13C NMR (CDCl3-d1) d 10.83
(CH2), 11.33 (CH3), 12.69 (CH), 22.69 (CH2), 92.92 (CH), 164.65 (C),
166.69 (C), 168.69 (C). ESI-MS calcd. for C9H11NO3, 181.19; found:
m/z 182.08 [MþH]þ. Anal. C9H11NO3 (C, H, N).
3-Ethyl-2-(3-methylbenzoyl)isoxazol-5(2H)-one (2j). Yield¼ 48%;
mp ¼81–84 C (EtOH). 1H NMR (CDCl3-d1) d 1.32 (t, 3H, CH2CH3,
J¼ 7.4 Hz), 2.40 (s, 3H, CH3-Ph), 3.09 (q, 2H, CH2CH3, J¼ 7.4 Hz),
5.41 (s, 1H, CH), 7.33–7.40 (m, 2H, Ar), 7.64–7.69 (m, 2H, Ar). 13C
NMR (CDCl3-d1) d 11.49 (CH3), 21.36 (CH3), 23.07 (CH2), 93.81 (CH),
127.02 (CH), 128.28 (CH), 130.23 (CH), 131.04 (C), 134.05 (CH),
138.28 (C), 163.38 (C), 166.20 (C), 166.66 (C). ESI-MS calcd. for
C13H13NO3, 231.25; found: m/z 232.09 [MþH]þ. Anal. C13H13NO3
(C, H, N).
3-Isopropyl-2-propionylisoxazol-5(2H)-one (2k). Yield¼ 47%;
mp¼ 92–95 C (EtOH). 1H NMR (CDCl3-d1) d 1.15 (t, 3H, CH2CH3,
J¼ 7.4 Hz), 1.23 (d, 6H, CH(CH3)2, J¼ 6.8 Hz), 2.72 (q, 2H, CH2CH3,
J¼ 7.4 Hz), 3.50–3.57 (m, 1H, CH(CH3)2), 5.27 (s, 1H, CH). 13C NMR
(CDCl3-d1) d 7.73 (CH3), 21.08 (CH3), 28.10 (CH), 28.54 (CH2), 91.70
(CH), 166.50 (C), 168.45 (C), 169.51 (C). ESI-MS calcd. for C9H13NO3,
183.20; found: m/z 184.09 [MþH]þ. Anal. C9H13NO3 (C, H, N).
2-(Cyclopropanecarbonyl)-3-isopropylisoxazol-5(2H)-one (2l).
Yield¼ 27%; mp¼ 55–57 C (EtOH). 1H NMR (CDCl3-d1) d 1.07–1.12
(m, 2H, CH2 cC3H5), 1.16–1.21 (m, 2H, CH2 cC3H5), 1.26 (d, 6H,
CH(CH3)2, J¼ 6.8 Hz), 2.38–2.45 (m, 1H, CH cC3H5), 3.54–3.61 (m 1H,
CH(CH3)2), 5.33 (s, 1H, CH).
13C NMR (CDCl3-d1) d 10.88 (CH2), 12.94
(CH), 21.17 (CH3), 28.18 (CH), 91.72 (CH), 166.50 (C), 168.45 (C),
169.51 (C). ESI-MS calcd. for C10H13NO3, 195.22; found: m/z 196.09
[MþH]þ. Anal. C10H13NO3 (C, H, N).
2-(Cyclopentanecarbonyl)-3-isopropylisoxazol-5(2H)-one (2m).
Yield¼ 23%; oil. 1H NMR (CDCl3-d1) d 1.26 (d, 6H, CH(CH3)2,
J¼ 6.8 Hz), 1.63–1.74 (m, 4H, 2CH2 cC5H9), 1.82–1.87 (m, 2H, CH2
cC5H9), 1.97–2.02 (m, 2H, CH2 cC5H9), 3.32–3.37 (m, 1H, CH cC5H9),
3.57–3.62 (m, 1H, CH(CH3)2), 5.30 (s, 1H, CH).
13C NMR (CDCl3-d1) d
21.12 (CH3), 25.95 (CH2), 28.17 (CH), 29.56 (CH2), 43.61 (CH), 91.66
(CH), 166.68 (C), 169.74 (C), 170.93 (C). ESI-MS calcd. for
C12H17NO3, 223.27; found: m/z 224.12 [MþH]þ. Anal. C12H17NO3
(C, H, N).
3-Isopropyl-2-(3-methylbenzoyl)isoxazol-5(2H)-one (2n).
Yield¼ 17%; oil. 1H NMR (CDCl3-d1) d 1.34 (d, 6H, CH(CH3)2,
J¼ 6.8 Hz), 2.41 (s, 3H, CH3-Ph), 3.70–3.78 (m 1H, CH(CH3)2), 5.42 (s,
1H, CH), 7.33–7.41 (m, 2H, Ar), 7.62–7.67 (m, 2H, Ar). 13C NMR
(CDCl3-d1) d 21.44 (CH3), 28.50 (CH), 92.85 (CH), 127.15 (CH),
128.30 (CH), 130.23 (CH), 131.38 (C), 134.08 (CH), 138.32 (C), 163.56
(C), 166.83 (C), 171.07 (C). ESI-MS calcd. for C14H15NO3, 245.27;
found: m/z 246.11 [MþH]þ. Anal. C14H15NO3 (C, H, N).
3-Isopropyl-2-(4-methylbenzoyl)isoxazol-5(2H)-one (2o).
Yield¼ 45%; mp ¼77–79 C (EtOH). 1H NMR (CDCl3-d1) d 1.33 (d,
6H, CH(CH3)2, J¼ 7.0 Hz), 2.41 (s, 3H, CH3-Ph), 3.66–3.79 (m 1H,
CH(CH3)2), 5.40 (s, 1H, CH), 7.26 (d, 2H, Ar, J¼ 8.0 Hz), 7.78 (d, 2H,
Ar, J¼ 8.0 Hz). 13C NMR (CDCl3-d1) d 21.91 (CH3), 22.30 (CH3), 29.05
(CH), 93.10 (CH), 129.04 (C), 129.66 (CH), 130.69 (CH), 144.82 (C),
163.72 (C), 167.36 (C), 171.67 (C). ESI-MS calcd. for C14H15NO3,
245.27; found: m/z 246.11 [MþH]þ. Anal. C14H15NO3 (C, H, N).
3-(3-Isopropyl-5-oxo-2,5-dihydroisoxazole-2-carbonyl)benzonitrile
(2p). Yield¼ 14%; oil. 1H NMR (CDCl3-d1) d 1.31 (d, 6H, CH(CH3)2,
J¼ 6.8 Hz), 3.00–3.09 (m, 1H, CH(CH3)2), 6.09 (s, 1H, CH), 7.70 (t, 1H,
Ar, J¼ 8.0 Hz), 7.96 (d, 1H, Ar, J¼ 8.0 Hz), 8.41 (d, 1H, Ar, J¼ 8.0 Hz),
8.46 (s, 1H, Ar). 13C NMR (CDCl3-d1) d 21.92 (CH3), 28.09 (CH), 86.78
(CH), 114.41 (C), 117.84 (C), 129.29 (C), 130.69 (CH), 134.65 (CH),
134.98 (CH), 138. 19 (CH), 159.16 (C), 164.82 (C), 172.17 (C).
IR¼ 1600 cm1 (C¼O amide), 1777 cm1 (C¼O ester), 2235 cm1
(CN). ESI-MS calcd. for C14H12N2O3, 256.26; found: m/z 257.09
[MþH]þ. Anal. C14H12N2O3 (C, H, N).
4-(3-Isopropyl-5-oxo-2,5-dihydroisoxazole-2-carbonyl)benzonitrile
(2q). Yield¼ 38%; mp¼ 113–115 C (EtOH). 1H NMR (CDCl3-d1) d
1.30 (d, 6H, CH(CH3)2, J¼ 7.2 Hz), 3.00–3.09 (m 1H, CH(CH3)2), 6.10
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(s, 1H, CH), 7.84 (d, 2H, Ar, J¼ 8.4 Hz), 8.29 (d, 2H, Ar, J¼ 8.0 Hz).
13C NMR (CDCl3-d1) d 21.29 (CH3), 27.48 (CH), 86.16 (CH), 117.46
(C), 118.11 (C), 131.03 (CH), 132.72 (CH), 158.88 (C), 164.28 (C),
171.60 (C). ESI-MS calcd. for C14H12N2O3, 256.26; found: m/z 257.09
[MþH]þ. Anal. C14H12N2O3 (C, H, N).
3-Isopropyl-2-(3-(trifluoromethyl)benzoyl)isoxazol-5(2H)-one (2r).
Yield¼ 21%; oil. 1H NMR (CDCl3-d1) d 1.39 (d, 6H, CH(CH3)2,
J¼ 6.8 Hz), 3.73–3.78 (m, 1H, CH(CH3)2), 5.51 (s, 1H, CH), 7.66 (t, 1H,
Ar, J¼ 7.6 Hz), 7.87 (d, 1H, Ar, J¼ 8.0 Hz), 8.09 (d, 1H, Ar, J¼ 8.0 Hz),
8.14 (s, 1H, Ar). 13C NMR (CDCl3-d1) d 21.83 (CH3), 29.12 (CH), 94.07
(CH), 127.33 (C), 129.64 (CH), 130.20 (C), 131.93 (C), 132.87 (CH),
133.45 (CH), 162.29 (C), 166.72 (C), 171.54 (C). ESI-MS calcd. for
C14H12F3NO3, 299.25; found: m/z 300.08 [MþH]þ. Anal.
C14H12F3NO3 (C, H, N).
3-Isopropyl-2-(4-(trifluoromethyl)benzoyl)isoxazol-5(2H)-one (2s).
Yield¼ 16%; oil. 1H NMR (CDCl3-d1) d 1.36 (d, 6H, CH(CH3)2,
J¼ 6.8 Hz), 3.69–3.77 (m 1H, CH(CH3)2), 5.47 (s, 1H, CH), 7.75 (d, 2H,
Ar, J¼ 8.0 Hz), 7.97 (d, 2H, Ar, J¼ 8.0 Hz). 13C NMR (CDCl3-d1) d
21.24 (CH3), 28.51 (CH), 93.46 (CH), 125.40 (CH), 127.30 (C), 130.09
(CH), 130.20 (C), 134.72 (C), 161.81 (C), 166.10 (C), 170.86 (C). ESI-
MS calcd. for C14H12F3NO3, 299.25; found: m/z 300.08 [MþH]þ.
Anal. C14H12F3NO3 (C, H, N).
General procedure for synthesis of compounds (3a,b). To a sus-
pension of the appropriate substrate 2l or 2n (0.36mmol) in 5ml
of anhydrous toluene, 0.72mmol of Lawesson’s reagent were
added. The mixture was stirred at reflux for 6 h, cooled, concen-
trated in vacuo, diluted with ice-cold water (10ml), and extracted
with ethyl acetate (3 15ml). The organic phase was dried over
sodium sulphate, and the solvent was evaporated in vacuo to
obtain the final compounds 3a,b, which were purified by column
chromatography using cyclohexane/ethyl acetate as eluent (ratio:
5:1 for 3a and 3:1 for 3b).
Cyclopropyl-(3-isopropyl-5-thioxoisoxazol-2(5H)-yl)methanone (3a).
Yield¼ 26%; oil. 1H NMR (CDCl3-d1) d 1.17–1.24 (m, 4H, 2CH2
cC3H5), 1.27 (d, 6H, CH(CH3)2, J¼ 6.8 Hz), 2.55–2.61 (m, 1H, CH
cC3H5), 3.54–3.61 (m, 1H, CH(CH3)2), 6.12 (s, 1H, CH).
13C NMR (CDCl3-
d1) d 10.88 (CH2), 14.76 (CH), 21.15 (CH3), 35.40 (CH), 106.37 (CH),
166.84 (C), 169.52 (C), 171.69 (C). ESI-MS calcd. for C10H13NO2S,
211.28; found: m/z 212.07 [MþH]þ. Anal. C10H13NO2S (C, H, N).
(3-Isopropyl-5-thioxoisoxazol-2(5H)-yl)-(m-tolyl)methanone (3b).
Yield¼ 40%; oil. 1H NMR (CDCl3-d1) d 1.32 (d, 6H, CH(CH3)2,
J¼ 6.4 Hz), 2.44 (s, 3H, CH3-Ph), 2.83–2.92 (m, 1H, CH(CH3)2), 7.05 (s,
1H, CH), 7.36–7.41 (m, 2H, Ar), 7.81–7.86 (m, 2H, Ar). 13C NMR (CDCl3-
d1) d 21.09 (CH3), 37.59 (CH3), 108.44 (CH), 122.51 (CH), 124.40 (CH),
127.37 (CH), 129.54 (CH), 131.38 (C), 134.14 (CH), 138.32 (C), 163.56
(C), 169.76 (C), 175.11 (C). ESI-MS calcd. for C14H15NO2S, 261.34;
found: m/z 262.09 [MþH]þ. Anal. C14H15NO2S (C, H, N).
General procedure for synthesis of compounds (4a,b). A mixture
of the appropriate intermediates (1a25 or 1f29) (0.63mmol), K2CO3
(1.26mmol), and 1-(chloromethyl)-3-methylbenzene (0.95mmol) in
2ml of anhydrous acetonitrile was stirred at reflux for 2 h. After
cooling, the mixture was concentrated in vacuo, diluted with ice-
cold water (10ml), and extracted with ethyl acetate (3 15ml).
The organic phase was dried over sodium sulphate, and the solv-
ent was evaporated in vacuo to obtain the final compounds 4a,b,
which were purified by column chromatography using cyclohex-
ane/ethyl acetate as eluent (ratio: 1:1 for 4a and 2:1 for 4b).
3,4-Dimethyl-2-(3-methylbenzyl)isoxazol-5(2H)-one (4a).
Yield¼ 26%; mp¼ 80–83 C (EtOH). 1H NMR (CDCl3-d1) d 1.73 (s,
3H, CH3), 2.13 (s, 3H, CH3), 2.32 (s, 3H, CH3-Ph), 4.59 (s, 2H, CH2),
7.03–7.12 (m, 3H, Ar), 7.20 (t, 1H, Ar, J¼ 7.6 Hz). 13C NMR (CDCl3-
d1) d 6.75 (CH3), 11.30 (CH3), 29.70 (CH3), 55.18 (CH2), 100.16 (C),
125.42 (CH), 128.63 (CH), 129.10 (CH), 129.19 (CH), 133.40 (C),
138.50 (C), 160.32 (C), 171.85 (C). ESI-MS calcd. for C13H15NO2,
217.26; found: m/z 218.11 [MþH]þ. Anal. C13H15NO2 (C, H, N).
3-Isopropyl-2-(3-methylbenzyl)isoxazol-5(2H)-one (4b).
Yield¼ 14%; oil. 1H NMR (CDCl3-d1) d 1.24 (d, 6H, CH(CH3)2,
J¼ 6.8 Hz), 2.33 (s, 3H, CH3-Ph), 2.73–2.79 (m, 1H, CH(CH3)2), 4.74
(s, 2H, CH2), 5.00 (s, 1H, CH), 7.02–7.07 (m, 2H, Ar), 7.12 (d, 1H, Ar,
J¼ 7.6 Hz), 7.22 (t, 1H, Ar, J¼ 7.4 Hz). 13C NMR (CDCl3-d1) d 21.41
(CH3), 21.60 (CH3), 26.58 (CH), 56.00 (CH2), 81.50 (CH), 124.93 (CH),
129.40 (CH), 133.87 (CH), 138.22 (C), 138.81 (CH), 141.50 (C), 171.51
(C), 174.09 (C). ESI-MS calcd. for C14H17NO2, 231.29; found: m/z
232.13 [MþH]þ. Anal. C14H17NO2 (C, H, N).
Procedure for synthesis of ethyl 4-methyl-5-oxo-2-(m-tolyl)-2,5-
dihydroisoxazole-3-carboxylate (4c). A mixture of dry CH2Cl2 (8ml),
1d28 (0.58mmol), 3-methylphenylboronic acid (1.16mmol),
Cu(Ac)2 (0.87mmol), and Et3N (0.87mmol) was stirred at room
temperature for 24 h. The organic layer was washed with water
(3 20ml), then with 33% aqueous ammonia (3 5ml). The
organic phase was dried over sodium sulphate, and the solvent
was evaporated in vacuo to obtain the final compound 4c, which
was purified by column chromatography using cyclohexane/ethyl
acetate 3:1 as eluent. Yield¼ 59%; oil. 1H NMR (CDCl3-d1) d 1.16
(t, 3H, CH2CH3, J¼ 7.2 Hz), 2.16 (s, 3H, CH3), 2.36 (s, 3H, CH3-Ph),
4.23 (q, 2H, CH2CH3, J¼ 7.2 Hz), 7.03–7.08 (m, 2H, Ar), 7.20 (d, 1H,
Ar, J¼ 7.6 Hz), 7.28 (t, 1H, Ar, J¼ 7.6 Hz). 13C NMR (CDCl3-d1) d
8.38 (CH3), 14.06 (CH3), 21.36 (CH3), 62.47 (CH2), 111.35 (C),
122.73 (CH), 126.24 (CH), 129.03 (CH), 130.60 (CH), 139.48 (C),
140.23 (C), 150.44 (C), 158.63 (C), 171.24 (C). ESI-MS calcd. for
C14H15NO4, 261.27; found: m/z 262.10 [MþH]þ. Anal. C14H15NO4
(C, H, N).
HNE inhibition assay. Compounds were dissolved in 100%
DMSO at 5mM stock concentrations. The final concentration of
DMSO in the reactions was 1%, and this level of DMSO had no
effect on enzyme activity. The HNE inhibition assay was performed
in black flat-bottom 96-well microtiter plates. Briefly, a buffer solu-
tion containing 200mM Tris–HCl, pH 7.5, 0.01% bovine serum
albumin, 0.05% Tween-20, and 20mU/ml of HNE (Calbiochem, La
Jolla, CA) was added to wells containing different concentrations
of each compound. The reaction was initiated by addition of
25 lM elastase substrate (N-methylsuccinyl-Ala-Ala-Pro-Val-7-
amino-4-methylcoumarin, Calbiochem) in a final reaction volume
of 100lL/well. Kinetic measurements were obtained every 30 s for
10min at 25 C using a Fluoroskan Ascent FL fluorescence micro-
plate reader (Thermo Electron, Waltham, MA) with excitation and
emission wavelengths at 355 and 460 nm, respectively. For all
compounds tested, the concentration of inhibitor that caused 50%
inhibition of the enzymatic reaction (IC50) was calculated by plot-
ting % inhibition versus logarithm of inhibitor concentration (at
least six points). The data are presented as the mean values of at
least three independent experiments with relative standard devia-
tions of <15%.
Analysis for compound stability
Spontaneous hydrolysis of selected derivatives was evaluated at
25 C in 0.05 M phosphate buffer, pH 7.3. Kinetics of hydrolysis
were monitored by measuring changes in absorbance spectra over
time using a SpectraMax Plus microplate spectrophotometer
(Molecular Devices, Sunnyvale, CA). Absorbance (At) at the charac-
teristic absorption maxima of each compound was measured at
the indicated times until no further absorbance decreases
occurred (A1)
30. Using these measurements, we created semilogar-
ithmic plots of log(At – A1) versus time, and k0 values were deter-
mined from the slopes of these plots. Half-conversion times were
calculated using t1/2¼0.693/k0, as described previously21.
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Molecular modelling
Initial structures of the compounds were generated with
HyperChem 8.0 (Shimadzu Corporation, Kyoto, Japan) and opti-
mised by the semi-empirical PM3 method. Docking of the mole-
cules was performed using Molegro Virtual Docker (CLC Bio,
København, Denmark) (MVD), version 4.2.0 (CLC Bio, København,
Denmark), as described previously22. The structure of HNE com-
plexed with a peptide chloromethyl ketone inhibitor31 was used for
the docking study (1HNE entry of the Protein Data Bank). The
search area for docking poses was defined as a sphere with a 10 Å
radius centred at the nitrogen atom in the five-membered ring of
the peptide chloromethyl ketone inhibitor. After removal of this
peptide and co-crystallised water molecules from the program
workspace, we set side chain flexibility for the 42 residues closest
to the centre of the search area22. Fifteen docking runs were
performed for each compound, with full flexibility of a ligand
around all rotatable bonds and side chain flexibility of the above-
mentioned residues of the enzyme. Parameters used within
Docking Wizard of the Molegro program were as described previ-
ously22. The docking poses corresponding to the lowest-energy
binding mode of each inhibitor were evaluated for the ability to
form a Michaelis complex between the hydroxyl group of Ser195
and the carbonyl group in the amido moiety of an inhibitor. For
this purpose, values of d1 [distance O(Ser195)C between the
Ser195 hydroxyl oxygen atom and the inhibitor carbonyl carbon
atom closest to O(Ser195)] and a [angle O(Ser195)C¼O, where
C¼O is the carbonyl group of an inhibitor closest to O(Ser195)]
were determined for each docked compound32. In addition, we
estimated the possibility of proton transfer from Ser195 to Asp102
through His57 (the key catalytic triad of serine proteases) by
 
 
Compound R2 R3 R4
2a cC3H5 CH3 CH3 
2b m-CH3-Ph CH3 CH3 
2c cC3H5 CH3 C2H5 
2d m-CH3-Ph CH3 C2H5 
2e cC3H5 C2H5 CH3 
2f m-CH3-Ph C2H5 CH3 
2g cC3H5 COOEt CH3 
2h m-CH3-Ph COOEt CH3 
2i cC3H5 C2H5 H 
2j m-CH3-Ph C2H5 H 
2k C2H5 iC3H7 H 
2l cC3H5 iC3H7 H
2m cC5H9 iC3H7 H 
2n m-CH3-Ph iC3H7 H 
2o p-CH3-Ph iC3H7 H 
2p m-CN-Ph iC3H7 H 
2q p-CN-Ph iC3H7 H 
2r m-CF3-Ph iC3H7 H 
2s p-CF3-Ph iC3H7 H 
3a cC3H5 iC3H7 H 
3b m-CH3-Ph iC3H7 H 
4a CH2-m-CH3-Ph CH3 CH3 
4b CH2-m-CH3-Ph iC3H7 H 
4c m-CH3-Ph COOEt CH3 
1 R3 R4 
a CH3 CH3 
b CH3 C2H5 
c C2H5 CH3 
d COOEt CH3 
e C2H5 H 
f iC3H7 H 
HN
O
O
R4
R3
1a-f
N
O
N
O
R3
R4
O
R2
O
R3
R4
O
R2
2a-s
4a-c
N
O
R3
S
R2
O 3a,b
c
for 1a, 1d and 1f
a
b
for 2l and 2n
R4
Scheme 1. Reagents and conditions: (a) R2-COCl, NaH, anhydrous THF, r.t., 24 h; (b) Lawesson’s reagent, toluene, reflux, 5 h; (c) for 4a,b: 3-methylbenzyl chloride,
K2CO3, anhydrous CH3CN, 80 C, 2 h; for 4c: 3-methylphenyl boronic acid, (CH3COO)2Cu, Et3N, anhydrous CH2Cl2, r.t., 24 h.
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calculating distances d2 between the NH hydrogen in His57 and
carboxyl oxygen atoms in Asp102, as described previously22. The
distance between the hydroxyl proton in Ser195 and the pyridine-
type nitrogen in His57 is also important for proton transfer.
However, because of easy rotation of the hydroxyl about the C–O
bond in Ser195, we measured distance d3 between the oxygen in
Ser195 and the basic nitrogen atom in His57. The effective length L
of the channel for proton transfer was calculated as L¼d3þmin (d2).
Crystallographic analysis
The data were collected at 100(2) K on Xcalibur3 CCD 4-circle dif-
fractometer using a graphite monochromator, Mo Ka radiation. A
reference frame was monitored every 50 frames to control the sta-
bility of the crystal, and the system revealed no intensity decay. The
data set was corrected for Lorentz, polarisation effects, and absorp-
tion corrections were performed by the ABSPACK33 multi-scan pro-
cedure of the CrysAlis data reduction package. The structure was
solved using the direct method with SUPERFLIP34 software, and the
refinement was carried out using the SHELXL-201335 software pack-
age. All non-hydrogen atoms were located from the initial solution
or from subsequent electron density difference maps during the ini-
tial course of the refinement. After locating the non-hydrogen
atoms, the models were refined against F2, first using isotropic and
finally anisotropic thermal displacement parameters. Hydrogen
atoms have been introduced as “riding hydrogens”. Programs used
in the crystallographic calculations included WinGX436 and
Mercury37 for graphics. Crystal structural data are available from the
Cambridge Crystallographic CCDC 1036557.
Results and discussion
Chemistry
The synthetic pathways leading to compounds 2a–s, 3a,b, and
4a–c are shown in Scheme 1. Compounds of type 2 were
obtained by treatment of the isoxazolones 1a–f25–29 with the
appropriate acyl/aroyl chloride and sodium hydride in anhydrous
tetrahydrofuran. Compounds 2l and 2n were further converted
into the corresponding thioxoisoxazolones 3a,b with Lawesson’s
reagent. Alkylation of 1a and 1f with 3-methylbenzyl chloride in
anhydrous acetonitrile and K2CO3 and of 1d with 3-methylphenyl
boronic acid, copper acetate, and triethylamine in anhydrous
dichloromethane by a coupling reaction resulted in 4a,b and 4c,
respectively. All of the final compounds were identified by 1H
NMR and 13C NMR. Moreover, heteronuclear multiple bond correl-
ation (HMBC) and heteronuclear single quantum coherence
(HSQC) two-dimensional NMR analyses were performed for repre-
sentative products. Finally, since the literature describes the pres-
ence of tautomer's of the isozazol-5(2H)-one nucleus38–40, a
crystallographic analysis of 2j (Figure 2) was performed in order to
univocally assign the structure (see Supplemental data).
Biological evaluation and structure–activity relationship (SAR)
analysis
All compounds were evaluated for their ability to inhibit HNE in
comparison with Sivelestat, a reference HNE inhibitor, and the
results presented in Table 1 demonstrated that the isoxazolone
nucleus is an appropriate scaffold for HNE inhibitor development.
These compounds display two carbonyl groups (2-N-CO and 5-CO)
as possible points of attack for Ser195, the amino acid of the HNE
active site responsible for the nucleophilic attack. The observation
that all 2-N-acyl/aroyl derivatives were active HNE inhibitors (2a–s),
while the 2-N-alkyl/aryl derivatives were completely inactive (4a–c),
seems to suggest that the carbonyl group involved in the catalysis
is the amidic carbonyl at position 2. Indeed, this observation is con-
sistent with our previous results for indazole derivatives21,22.
The presence of small alkyl groups at positions 3 and 4 (2a–f)
led to compounds with HNE inhibitory activity in the micromolar/
submicromolar range, whereas the introduction at position 3 of a
carbethoxy group (2g,h) gave different results, depending on the
substituent at N-2. The elimination of methyl group at position 4
(2i–2s) resulted in compounds endowed with excellent inhibitory
activity, indicating the importance of the unsubstitution of this pos-
ition. This fact can be highlighted by compounds 2i and 2j which
show 22- and 42-fold higher inhibitory activity (IC50¼96 and 43 nM,
respectively) with respect to the corresponding 4-methyl deriva-
tives 2e and 2f (IC50¼2.2 and 1.8 lM, respectively). On the other
hand, in the 4-unsubstituted series, compounds 2l, 2n, 2o, and 2s
also exhibited IC50 values in the nanomolar range (20–42 nM).
Moreover, substitution of the methyl at 2-benzoyl group in the
potent compounds 2n and 2o with a trifluoromethyl group (2r and
2s) did not affect inhibitory activity when the substituent was in
the para position of the benzoyl group (i.e. compounds 2o and 2s
Figure 2. X-ray structure of compound 2j.
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with IC50¼20 and 34 nM, respectively) but resulted in loss of activity
when the substituent was in the meta position.
To evaluate the importance of the 5-CO group, which does not
seem to be involved in catalysis, we synthesised 3a and 3b as
thio analogues of the two potent compounds 2l and 2n. However,
the low activity (3a, IC50¼2.1lM) or inactivity (3b) of these new
products clearly suggests that the 5-CO group is important for
interaction with the target. To assess if this inactivity was the
result of increased bulkiness and/or a weaker H-binding acceptor
effect of sulphur versus oxygen in the carbonyl or if it was related
to other reasons, we performed molecular modelling studies.
Molecular modelling
To further investigate the interaction of these new compounds
with HNE, molecular docking of isoxazolones derivatives 2l, 2n,
2o, 2q, 3a, and 3b into the HNE binding site (1HNE entry of
Protein Data Bank) was performed. Side chains of selected residues
in the HNE binding site were considered flexible, as described in
our previous modelling studies22,24. According to the docking
scores DE of the poses (Table 2), isoxazolones are effectively anch-
ored within HNE binding site. However, it is well-known that cata-
lytic activity of serine proteases is related to synchronous proton
transfer from serine via histidine to aspartate residues41. In HNE,
this catalytic triad corresponds to Ser195, His57, and Asp102,
respectively. The length of the proton transfer channel is charac-
terised by the magnitude of L (see Table 2). Additionally, effective-
ness of HNE binding to a ligand depends on its ability to form a
Michaelis complex between a carbonyl group of the ligand and an
oxyanion hole centred at the hydroxyl oxygen atom of Ser195.
Geometry which favours Michaelis complex formation corresponds
to ligand orientation with angle a values from 80 to 120 and
with shortened distance d1 (1.8–2.6 Å)
41 (Table 2). Although a low-
Table 1. HNE inhibitory activity of isoxazolone derivatives 2a–s, 3a,b, 4a–c.
N
O
O
R2
R2R2
R4
R4
R3
R3
(4a-c)
N
O
O
O (2a-s)
N
O
S
O (3a,b)
Compound R2 R3 R4 IC50 (lM)
a
2a cC3H5 CH3 CH3 0.12 ± 0.023
2b m-CH3-Ph CH3 CH3 10.9 ± 1.2
2c cC3H5 CH3 C2H5 0.13 ± 0.025
2d m-CH3-Ph CH3 C2H5 0.094 ± 0.023
2e cC3H5 C2H5 CH3 2.2 ± 0.28
2f m-CH3-Ph C2H5 CH3 1.8 ± 0.32
2g cC3H5 COOEt CH3 0.44 ± 0.14
2h m-CH3-Ph COOEt CH3 39.7 ± 5.1
2i cC3H5 C2H5 H 0.096 ± 0.022
2j m-CH3-Ph C2H5 H 0.043 ± 0.011
2k C2H5 iC3H7 H 1.1 ± 0.14
2l cC3H5 iC3H7 H 0.034 ± 0.009
2m cC5H9 iC3H7 H 0.56 ± 0.15
2n m-CH3-Ph iC3H7 H 0.042 ± 0.011
2o p-CH3-Ph iC3H7 H 0.020 ± 0.007
2p m-CN-Ph iC3H7 H 6.5 ± 1.7
2q p-CN-Ph iC3H7 H 18.2 ± 2.5
2r m-CF3-Ph iC3H7 H 1.2 ± 0.22
2s p-CF3-Ph iC3H7 H 0.034 ± 0.012
3a cC3H5 – – 2.1 ± 0.31
3b m-CH3-Ph – – NA
b
4a CH2-m-CH3-Ph CH3 CH3 NA
b
4b CH2-m-CH3-Ph iC3H7 H NA
b
4c m-CH3-Ph COOEt CH3 NA
b
Sivelestat – – – 0.050 ± 0.020
aIC50 values are presented as the mean ± SD of three independent experiments.
bNA: no inhibitory activity was found at the highest concentration of compound tested (50 lM).
Table 2. Biological activities, geometric parameters, and docking scores of the enzyme–inhibitor complexes predicted by molecular docking with MVD.
Comp. IC50 (lM)
a a d1 d2 d3 L
b
Docking score
DE (kcal/mol)
2lc 0.034 85.2 2.903 2.763, 3.967 2.829 5.592 –58.9
3a 2.1 139.6 4.148 2.379, 3.611 2.560 4.939 –44.0
2n 0.042 81.6 3.861 2.399, 3.627 2.596 4.995 –34.2
3b NA 148.3 4.659 2.750, 3.962 2.849 5.599 –21.1
2oc 0.020 104.1 3.134 2.760, 3.975 2.819 5.579 –67.6
2qc 18.2 89.4 4.500 3.130, 4.319 3.286 6.416 –58.4
aHNE inhibitory activity.
bThe length of the proton transfer channel was calculated as L¼d3þmin(d2).
cAccording to the docking results, a Michaelis complex with Ser195 is formed with participation of the ester carbonyl group.
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energy docking pose of each ligand is not completely identical to
the Michaelis complex, they must have certain similarity. Hence, it
is reasonable to use the geometry of the low-energy pose to
evaluate possibility of complex formation.
Compounds 2l, 2n, 2o, 2q, 3a, and 3b occupy an area in the
HNE binding site in the vicinity of the terminal part of the
co-crystallised peptide. As presented in Table 2, the sulphur-con-
taining compounds 3a and 3b had larger distances d1 (4.148 Å
and 4.659 Å, respectively) than their counterparts 2l and 2n and
were characterised by an angle a that was not suitable for easy
formation of a Michaelis complex (139.6 and 148.3, respectively).
The different orientation within the binding site of sulphur
Figure 3. Docking poses of compounds 2n (lower compound) and 3b (upper compound). The ovals represent the C¼S and C¼O fragment of the two compounds,
respectively. Residues within 6 Å from the co-crystallized ligand are shown.
Figure 4. Docking pose of compound 2o. Residues within 3 Å of the pose are visible. The H-bond is shown by a dashed line and is indicated by the arrow.
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compounds, with respect to compounds containing the 5-carbonyl
group could also be caused by higher values of C¼S bond length
and radius of the sulphur atom (Figure 3).
From the docking studies, it is interesting to note that these
isoxazolone compounds show involvement of the endocyclic car-
bonyl group in formation of a Michaelis adduct, but also the
amide carbonyl group is important for proper anchoring of the
ligands to the enzyme pocket. For example, compounds 2o and
2q show values of angle a in the exact range (Table 2) and are
located similarly in the HNE binding site to allow formation a
Michaelis complex with the endocyclic carbonyl group. In particu-
lar, inhibitor 2o, which has the best inhibitory activity
(IC50¼20 nM) forms a hydrogen bond between the oxygen of the
5-carbonyl group and the NH group of Ser195 (Figure 4) that likely
improves the enzyme-ligand orientation, in addition to the
involvement of the 5-carbonyl carbon atom and the Ser195
hydroxyl group, for the formation of the Michaelis complex.
In compound 2q, the 5-carbonyl group (carbon atom) is
located at a longer distance d1 from Ser195 than that of 2o (see
Table 2). This is due to the H-bond interaction of the oxygen atom
of the 5-carbonyl group that involves the NH group of Gly193
instead of the NH group of Ser195. Moreover, for derivative 2q,
the imidazole ring of His57 is rotated unfavourably, thus enhanc-
ing the length L of the proton transfer channel (Table 2).
Consequently, the conditions for formation of a Michaelis complex
are not as suitable and lead to reduced inhibitory activity
(IC50¼18.2 lM). Differences between 2o and 2q, which are p-tolyl-
and p-cyanophenyl derivatives, respectively, could also likely be
related to variations in hydrophobicity, polarity of substituents,
and different orientation of flexible side chains in the ligand–en-
zyme complex. Thus, our docking studies indicate that the 2-
amido carbonyl group also plays an important role in positioning
the ligand within the binding site, although the attack of the
Ser195 is directed at the endocyclic C¼O group (5-carbonyl
group).
The sum of non-bonding interaction energies between HNE
and the two atoms of the amido carbonyl moiety of 2o equals
–12.86 kcal/mol, which is even more negative than for the endocy-
clic carbonyl (–9.11 kcal/mol), indicating a strong interaction with
the enzyme. Non-specific Van der Waals interaction by the tolyl
ring and/or polar interactions by the 2-amido group are respon-
sible for proper anchoring of 2o to the sub-pocket of the binding
site surrounded by Cys191, Phe192, Phe215, Val216, and Cys220.
Although 2q shows these nonspecific interactions with the
sub-pocket binding site, the different orientation in the enzyme
pocket caused by the H-bond interaction of the oxygen atom of
the 5-carbonyl group involving the NH Gly193 (see above) could
explain the lower inhibitory activity compared to 2o.
Stability and kinetic features
The most potent seven isoxazolones with IC50<100 nM were fur-
ther evaluated for chemical stability in aqueous buffer using spec-
trophotometry to detect compound hydrolysis. The compounds
had t1/2 values from 3.1 to 19.3 h for spontaneous hydrolysis
(Table 3), indicating that these isoxazolones were more stable
than our previously described HNE inhibitors with N-benzoylinda-
zole scaffolds21,22. We also tested compound hydrolysis in the
presence of HNE and found that the speed of hydrolysis gradually
increased with increasing enzyme concentration. As an example,
Figure 5 shows dose-dependent hydrolysis of compound 2i over
time (Figure 5). In the presence of 400mU/ml HNE, the hydrolysis
was 2.2–4.8-fold higher than for spontaneous hydrolysis (i.e. with-
out HNE) (Table 3).
We also evaluated reversibility of the HNE-inhibitor complex
over time for most potent compounds. As shown in Figure 6, HNE
inhibition was maximal during the first 30min for compounds 2n,
2d, 2l, 2i, and 2j. However, inhibition by compound 2s was
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Figure 6. Evaluation of HNE inhibition by selected isoxazolone derivatives. HNE
was incubated with the indicated compounds at 5lM concentrations, and kinetic
curves monitoring substrate cleavage catalysed by HNE are shown. Representative
curves are from three independent experiments.
Table 3. Half-life (t1/2) for the hydrolysis of selected isoxazolone derivatives in
aqueous buffer and in the presence of HNE.
t1/2 (h)
Compd. Max (nm)a Spontaneous hydrolysis In the presence HNEb
2d 290 7.7 3.5
2i 275 19.3 4.0
2j 285 5.3 2.1
2l 275 19.3 4.3
2n 285 6.2 2.6
2o 290 8.9 3.4
2s 285 3.1 0.9
aAbsorption maximum of the compounds for monitoring hydrolysis.
bHydrolysis was monitored in the presence of 400mU/ml HNE.
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Figure 5. Analysis of compound 2i spontaneous hydrolysis. Compound 2i (80lM)
was incubated in 0.05 M phosphate buffer (pH 7.5, 25 C) supplemented with 0,
50, 200, and 400lg/ml HNE, as indicated. Spontaneous hydrolysis was monitored
by measuring changes in absorbance at 275 nm (absorption maximum of com-
pound 2i) over time. The data are presented as the mean ± SD of triplicate sam-
ples from one experiment, which is representative of two independent
experiments.
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reversed after 10min. The most stable inhibition was found for 2o,
where inhibition of HNE activity was reversed only after 2 h
(Figure 6). To better understand the mechanism of action of this
isoxazolone HNE inhibitor, we performed additional kinetic experi-
ments. As shown in Figure 7, the representative double-reciprocal
Lineweaver–Burk plot of fluorogenic substrate hydrolysis by HNE
in the absence and presence of compound 2o indicates that this
compound is a competitive HNE inhibitor.
Conclusions
In conclusion, the present study demonstrates that the isoxazo-
lone nucleus is an appropriate scaffold for the development of
potent HNE inhibitors. The most potent compounds were the 4-
unsubstituted derivatives. In particular, compounds 2o and 2s,
had IC50 values of 20 nM and 34 nM, respectively. Docking studies
suggest that, differently from our previous N-benzoylindazoles
compounds21,22, the attack of Ser195 is directed at the endocyclic
C¼O group at position 5 but also that the amidic C¼O group is
important for anchoring to the sub-pocket of the binding site sur-
rounded by Cys191, Phe192, Phe215, Val216, and Cys220 through
nonspecific van der Waals and polar interactions. This hypothesis
is in agreement with the inactivity of the N-alkyl/aryl derivatives
and the thioanalogues. Studies of chemical stability indicated that
the new isoxazolones are more stable than the compounds we
previously studied21–24, with t1/2 values from 3.1 to 19.3 h, and
that they were competitive HNE inhibitors. Thus, this new class of
HNE inhibitors has great potential for the development of potent
and relatively stable HNE inhibitors.
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